Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4768 晶呈科技. Please read: https://finlab.finance/en/setup?stock=4768

No install, open FinLab Studio

4768

晶呈科技 Chemicals As of 2026-06-17 Updated daily after market close

quality needs a look, premium valuation.

1 active signal

Revenue ≥20%

This page refreshes daily after the close. Add 晶呈科技 to your watchlist to track signal changes on your next visit.

Is 晶呈科技 a buy? Fundamentals and valuation first

Weak profitability.Operating margin is in the 20th market percentile. Latest quarterly ROE ≈ -1.9%.
Valuation is high.PE is in the 99th market percentile; within its own history, PE is around the 99th percentile.
Foreign investors are net selling.Foreign 20-day net flow ≈ -5.5% of volume (net sell).
Strong revenue growth.Latest monthly revenue YoY ≈ 64.2%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bearish -0.52

BearishNeutralBullish

Distribution to retail — bearish

Distribution to retail — bearish
兆豐-松德 holds 267 lots
sellers have 248 lots left, ~26 sessions to clear

Window from 2026-01-17 · Price -9% · branches to 2026-06-17· TDCC to 2026-06-12

Largest holder 兆豐-松德 has accumulated 267 lots since the start (sold 2%), now trimming.
Main distributor 凱基-信義 peaked at 447 lots, has sold 60%, 179 left, paused recently.
TDCC big holders (absolute) >1000-lot holders -8.20pp, mid holders -5, retail +9.76pp — drifting down to retail.
Foreign hedge-desk net short Net short -2,169 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).

Branch inventory reconstruction

Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.

Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.

Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.

Accumulating

兆豐-松德宏遠-館前國泰-敦南台新-大裕元富中國信託-高雄

Distributing

凱基-信義摩根大通永豐金證券玉山-板橋國票-博愛凱基

Desks

own scale

國泰證券港商野村台灣摩根士丹利凱基-台北

Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline

Branch details Unit: lots

Accumulating

兆豐-松德 +267

sold 2%
宏遠-館前 +150

sold 0%
國泰-敦南 +140

sold 0%· still adding
台新-大裕 +125

sold 0%
元富 +118

sold 0%
中國信託-高雄 +94

sold 10%· still adding

Distributing

凱基-信義 179 left

sold 60%· paused recently
摩根大通 51 left

sold 86%· ~5 sessions to clear
永豐金證券 25 left

sold 87%· ~2 sessions to clear
玉山-板橋 33 left

sold 73%· ~8 sessions to clear
國票-博愛 59 left

sold 50%· ~10 sessions to clear
凱基 21 left

sold 76%· paused recently

Desks

國泰證券 -898

unclassified
港商野村 -852

hedge desk · will cover
台灣摩根士丹利 -690

hedge desk · will cover
凱基-台北 -570

day-trade · selling pressure

Still selling 248 lots ~26 sessions to bottom at most

Recent buy/sell force +582 absorbed / -380 sold buyers slightly ahead

Hedge-desk net short -1,556 lots potential cover-buying, not selling pressure

TDCC big holders · absolute-holding cross-check

>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 64.24%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

54 historical occurrences (since 2022-04-13)

120 days after: historical avg +15.79%

20-day +3.61%

60-day +11.95%

120-day +15.79%

20-day

60-day

120-day

Win

50%

57.1%

60%

Sample

Median

-1.37%

+2.68%

+3.37%

Excess

+1.34%

+6.24%

+3.88%

Beat mkt rate

23.3%

35.7%

32%

Over 25 occurrences, 120-day forward avg gained 15.79%, beat the market by 3.88 pts; win rate 60%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

0-20 Insufficient data

20-40 Insufficient data

40-60 Insufficient data

60-80 Insufficient data

80-100 Insufficient data Now

PE percentile band	Sample days	240-day avg return
0-20	0	Insufficient data
20-40	0	Insufficient data
40-60	1	Insufficient data
60-80	0	Insufficient data
80-100 You are here	0	Insufficient data

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 1264.1, at the 98.6th percentile of its own history (80-100 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation

Momentum

Cheap (own-history bottom 1/3)

Mid

Expensive (own-history top 1/3)

60-day momentum up

Insufficient data
(0d)

Insufficient data
(19d)

Now

+144.2%

Win rate 100% Excess +107%

59d

60-day momentum down

Insufficient data
(0d)

+176.3%

Win rate 100% Excess +146.5%

43d

Insufficient data
(0d)

Currently in “Expensive (own-history top 1/3) × 60-day momentum up”: across 59 historical days, 120-day forward avg gained 144.2%, win rate 100%, beat the market by 107%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

6 times historically; 60-day forward avg +24.29%, win rate 80%, beating the market by +10.95 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

11 times historically; 60-day forward avg +19.3%, win rate 50%, beating the market by +10.79 pts on average.

What does 晶呈科技 do? Company profile

化學工業；半導體特殊材料、電子級特殊氣體與濕式化學品櫃買中心上櫃

Overview

4768 對應晶呈科技股份有限公司，為櫃買中心上櫃普通股，非 ETF、ETN、權證或特別股。公司成立於 2010/12/16，總部位於苗栗縣竹南鎮公義路 462 巷 58 號，2022/04/13 上櫃掛牌。董事長兼總經理為陳亞理，發言人張永宏。Yahoo 股市資料顯示股本為新台幣 474,879,690 元、已發行普通股 47,487,969 股；2024 年報列示 2025/03/29 流通在外普通股 45,226,638 股，後續因股利配股等使股本增加。員工規模依 2024 年報：2024 年底 129 人、2025/03/31 為 137 人，其中研發 32 人、製造 51 人。主要股東依 2025/03/29 年報：陳亞理 12.52%、國泰人壽全權委託國泰投信投資帳戶（台股十五）6.66%、郭淑齡 2.66%、張惟傑 2.31%、張坤祥 2.01%、張惟森 1.71%、張登凱 1.68%、張永宏 1.48%、詹偉明 1.47%、湯文萬 1.31%。重要轉投資包含南京晶咏呈新材料有限公司、亞欣達特殊材料、台灣芯電應用科技、創視媒體科技等。

Business

晶呈科技由半導體與太陽能產業設備、材料代理起家，逐步轉型為半導體先進材料製造商。主要業務為精密化學品之生產製造與銷售、特殊材料銷售與代理、精密設備暨零組件銷售與代理。核心產品是半導體製程特殊氣體，包含 C4F8、SiF4、C3F8、C4F6、CH2F2、F2 mixture、SF6、Xe、Kr、Neon 與 Neon mixture 等，應用於黃光、蝕刻、薄膜、擴散/離子植入、設備清洗與雷射製程；另有 ReBirth 矽晶圓重生服務、CMW/銅磁晶片、CMµLED、TransVivi Pixel、半導體級 Stripper 去光阻液、TGV 玻璃通孔基板與太陽能相關雷射設備、鎢繩等零組件。2024 年產品營收結構：精密化學品 969,268 仟元、占 95.32%；特殊材料 13,392 仟元、占 1.32%；精密設備暨零組件 11,145 仟元、占 1.09%；勞務收入暨其他 23,055 仟元、占 2.27%。2025 年前三季法說資料顯示營收 581,679 仟元，其中特殊氣體 530,571 仟元、占 91.21%；濕式化學品 17,297 仟元、占 2.97%；其他 33,811 仟元、占 5.82%。2025 年全年公開營收資料為 1,229,279 仟元、年增 20.89%；新聞報導稱 2025 年稅後純益 1,868 萬元、EPS 0.39 元。商業模式包含自製高純度特殊氣體、濕式化學品與先進材料，並搭配部分代理商品與代工服務；客戶集中於半導體晶圓製造、封測、平面顯示器、Mini/Micro LED、太陽能與半導體材料供應鏈。年報揭露 2024 年前兩大客戶為代號 C016（國內半導體代工大廠，銷售占 46.71%）與 C117（中國特種氣體供應商，銷售占 14.65%），公司未公開客戶全名。

Outlook 2025–2028

2025 至 2028 年核心觀察為特殊氣體在地化、先進封裝 TGV、Stripper 去光阻液與晶圓重生服務能否放量。公司 2025 年第三季法說指出，2025 年前三季營收與獲利低於 2024 年同期，主因雷射氣體報價下跌、出口原物料成本上升與研發/擴產費用增加；但 2025 年第四季起特殊氣體鋼瓶出貨展望提高，並設定 2026 年特殊氣體 C4F6、F2/N2 營收成長目標大於 30%，TGV 成長目標大於 100%，Stripper 成長目標大於 50%，TransVivi display 成長目標大於 30%。製造面，一廠量產 C4F8、C4F6、Laser Gas、全品項特氣四級製造、ReBirth Phase 1 與 TransVivi Pixel Phase 1；二廠量產/試產 Stripper、TGV LADY Glass Core Line 1、F2，並裝機 BCl3、AHF；三廠規劃 C4F6 一級製造設備自製廠與 250T 合成工廠，法說資料估 2026 年第二季完工。年報短期計畫包括提升特殊氣體、ReBirth 與貿易商品市占率、建立 ReBirth 月產 4 萬片產能、建立 TGV 月產 1 萬片產能；長期計畫包括增加特殊氣體品項、拓展韓國、印度、日本、美國、歐洲與新加坡市場、擴大 TGV 銷售市占率、發展 Mini/Micro LED 相關產品。產業動能來自 AI/HPC、先進製程、記憶體復甦、半導體材料國產化、先進封裝玻璃基板與環保替代清腔/去光阻材料需求。主要風險包括：客戶集中度高、特氣價格波動、原物料與稀有氣體供應波動、擴產時程與認證不確定、TGV/Stripper 新產品量產良率與客戶導入不確定、研發與資本支出墊高、負債比上升、半導體景氣循環、國際競爭者技術與價格競爭、化學品/毒化物法規與環安風險。2027 至 2028 的具體營收數字未見公司正式財測，僅能推估成長將取決於 2026 後三廠 C4F6、TGV、Stripper 產能利用率與海外客戶認證進度。

Supply Chain

Upstream

Fluorine 2024 年報列為主要進貨供應商之一，年報未揭露完整法人名稱與掛牌資訊，推定為氟系原料或特殊氣體相關供應商，非可確認台股上市櫃公司。
ASTOR 2024 年報列為主要進貨供應商之一，年報未揭露完整法人名稱與掛牌資訊，非可確認台股上市櫃公司。
史密斯 2024 年報列為主要進貨供應商之一，與發行人關係欄標示為是；年報未揭露完整法人名稱與掛牌資訊，非可確認台股上市櫃公司。
石化副產品或基礎原料分解/合成製造商年報產業鏈圖列示晶呈位於乾式/濕式化學品製造環節，上游包含石化副產品、基礎原料分解與合成製造；具體供應商多未公開。
玻璃砂與無鹼玻璃製造商 TGV 玻璃通孔基板上游可能包含玻璃砂、無鹼玻璃與精密玻璃材料供應；年報僅揭露產業鏈類別，未確認特定供應商。

Downstream

C016（未揭露國內半導體代工大廠） 2024 年報列為第一大客戶，銷售額 474,930 仟元、占 46.71%；公司僅揭露為國內半導體代工大廠，銷售半導體蝕刻製程所需特殊氣體，未揭露全名，故 stock_id 設為 null。
C117（未揭露中國特種氣體供應商） 2024 年報列為第二大客戶，銷售額 148,983 仟元、占 14.65%；公司說明為中國特種氣體供應商，非台股掛牌或未能確認台股掛牌。
半導體晶圓製造與封測客戶特殊氣體、Stripper、ReBirth 與 TGV 主要下游；終端應用包含黃光、蝕刻、薄膜、擴散/離子植入、設備清洗、高階封裝與測試晶圓回收。
平面顯示器與 LTPS-AMOLED 客戶雷射氣體 XeCl 可應用於 LTPS 電晶體回火製程；客戶多未具名。
Mini/Micro LED 與大型顯示器客戶 CMW、CMµLED 與 TransVivi Pixel 應用於 Mini/Micro LED 顯示與大型顯示器，具體客戶未公開。

Competitors

英特格 Entegris 美國上市公司；年報列為氟碳類蝕刻氣體與 Stripper 去光阻液競爭者。
昭和電工/Resonac 日本上市/集團公司；年報列為氟碳類蝕刻氣體競爭者。
關東電化工業日本上市公司；年報列為氟碳類蝕刻氣體競爭者。
日本中央硝子日本上市公司；年報列為氟碳類蝕刻氣體競爭者。
Foosung Group 韓國上市/集團公司；年報列為氟碳類蝕刻氣體競爭者。
NOVA 美國公司；年報列為稀有類雷射氣體競爭者。
普萊克斯 Praxair 美國公司，現屬 Linde 集團；年報列為稀有類雷射氣體競爭者。
林德聯華林德集團在台相關氣體業者；年報列為稀有類雷射氣體競爭者，非台股上市櫃。
法國液化空氣 Air Liquide 法國上市公司；年報列為稀有類雷射氣體競爭者。
艾爾斯半導體（台灣 RS Tech）日本 RS Technologies 在台子公司；年報列為再生晶圓競爭者，母公司於東京證交所掛牌，非台股。
中砂 1560 台股上市公司；年報列為再生晶圓競爭者。
辛耘 3583 台股上市櫃公司；年報列為再生晶圓競爭者。
杜邦 DuPont 美國上市公司；年報列為 Stripper 去光阻液競爭者。
3M 美國上市公司；年報列為 Stripper 去光阻液競爭者。
AGC 日本上市公司；年報列為玻璃通孔基板競爭者。
Dow Corning 陶氏集團相關品牌/事業；年報列為玻璃通孔基板競爭者，非台股。
友晁能源材料台灣未公開發行公司；年報列為雷射設備競爭者。
Innolas 法國/歐洲雷射設備公司；年報列為雷射設備競爭者，非台股。
MAMZ Group 德國設備業者；年報列為雷射設備競爭者，非台股。

Sources（11）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
Excess return is measured against the TAIEX total-return index (dividends included).
Valuation regime and percentile stats use an expanding own-history window (no future data).
Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.